Yahoo Web Search

Search results

  1. Feb 9, 2023 · On an adjusted basis, 2022 net income attributable to Baxter totaled $1.8 billion, or $3.50 per diluted share, a decline of 3% compared to the prior-year period. For the full year, Baxter generated $1.2 billion in operating cash flow from continuing operations and $532 million in free cash flow (operating cash flow from continuing operations ...

  2. Feb 9, 2023 · The accompanying schedules include additional details on sales performance by product categories and segments. For full-year 2022, net income (loss) attributable to Baxter totaled ($2.4 billion), or ($4.83) per diluted share on a U.S. GAAP basis.

  3. Feb 17, 2022 · On an adjusted basis, 2021 net income attributable to Baxter totaled $1.8 billion, or $3.61 per diluted share, an increase of 17% compared to the prior-year period. Adjusted results for full-year 2021 include a contribution to earnings of $0.08 per diluted share from Hillrom.

  4. Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant currency basis and approximately 3% on an operational basis. Baxter expects full-year U.S. GAAP EPS of $2.35 to $2.43 and adjusted EPS of $4.12 to $4.20.

  5. Apr 28, 2022 · First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14; Adjusted EPS totaled $0.93. Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, 25% to 26% on a constant...

  6. Feb 17, 2022 · On the call this morning, we will be discussing Baxter's fourth quarter and full year 2021 financial results along with our financial outlook for 2022.

  7. People also ask

  8. Feb 21, 2024 · Baxter is an established market leader in big pharma and medical supplies, with expected EPS growth and declining debt. Learn why BAX stock is a Buy.

  1. People also search for